Opko Health (OPK) Current Deferred Revenue (2014 - 2024)

Opko Health's (OPK) quarterly Current Deferred Revenue came in at $6000.0 in Q4 2024, down 14.29% YoY from $7000.0 in Q1 2024, and down 14.29% on a QoQ basis from $7000.0 in Q4 2023.

Opko Health (OPK) Current Deferred Revenue (2014 - 2024) Analysis & Trends

Opko Health (OPK) has 4 years of Current Deferred Revenue data on file, last reported at $6000.0 in Q4 2024.

  • Quarterly Current Deferred Revenue fell 14.29% year-over-year to $6000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $6000.0 (down 14.29% YoY) and the FY2024 annual result came in at $6000.0, down 14.29% from the prior year.
  • Current Deferred Revenue eased to $6000.0 in Q4 2024, from $7000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7000.0 in Q4 2023 to a low of $6000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 213.88 Bn 209.81 Bn 8.34 Bn
2 Danaher 140.65 Bn 136.30 Bn 3.61 Bn
3 Idexx Laboratories 46.02 Bn 45.83 Bn 779.09 Mn
4 Agilent Technologies 39.85 Bn 38.05 Bn 990.00 Mn
5 Iqvia Holdings 39.20 Bn 37.12 Bn 1.44 Bn
6 Natera 38.80 Bn 37.70 Bn 696.04 Mn
7 Illumina 30.11 Bn 28.94 Bn 770.00 Mn
8 Mettler Toledo International 28.66 Bn 28.61 Bn 650.22 Mn
9 Quest Diagnostics 26.24 Bn 25.61 Bn 1.03 Bn
10 Opko Health 1.02 Bn 718.85 Mn 80.02 Mn

Historic Data

Download Data
DateValue
Dec 31, 2024 6,000.00
Dec 31, 2023 7,000.00
Sep 30, 2015 254.10 Mn
Dec 31, 2014 6.70 Mn